Literature DB >> 32265523

IL-23 inhibitor guselkumab shows promise for PsA.

Jessica McHugh1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32265523     DOI： 10.1038/s41584-020-0420-6

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  2 in total

1.  Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial.

Authors:  Atul Deodhar; Philip S Helliwell; Wolf-Henning Boehncke; Alexa P Kollmeier; Elizabeth C Hsia; Ramanand A Subramanian; Xie L Xu; Shihong Sheng; Prasheen Agarwal; Bei Zhou; Yanli Zhuang; Christopher T Ritchlin
Journal:  Lancet       Date:  2020-03-13       Impact factor: 79.321

2.  Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial.

Authors:  Philip J Mease; Proton Rahman; Alice B Gottlieb; Alexa P Kollmeier; Elizabeth C Hsia; Xie L Xu; Shihong Sheng; Prasheen Agarwal; Bei Zhou; Yanli Zhuang; Désirée van der Heijde; Iain B McInnes
Journal:  Lancet       Date:  2020-03-13       Impact factor: 79.321
  2 in total
  2 in total

Review 1.  Phage Display Derived Monoclonal Antibodies: From Bench to Bedside.

Authors:  Mohamed A Alfaleh; Hashem O Alsaab; Ahmad Bakur Mahmoud; Almohanad A Alkayyal; Martina L Jones; Stephen M Mahler; Anwar M Hashem
Journal:  Front Immunol       Date:  2020-08-28       Impact factor: 7.561

Review 2.  The Role of the IL-23/IL-17 Pathway in the Pathogenesis of Spondyloarthritis.

Authors:  Hiroyuki Tsukazaki; Takashi Kaito
Journal:  Int J Mol Sci       Date:  2020-09-03       Impact factor: 5.923
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.